ArticleIranian journal of basic medical sciences2016
Anti-inflammatory effect of Yu-Ping-Feng-San
Article in Iranian journal of basic medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study.International journal of chronic obstructive pulmonary diseaseTrial
- Yu-Ping-Feng-San mitigates development of emphysema and its exacerbation induced by influenza virus in mice.Chinese herbal medicines · 2026Article
- Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence.Drug design, development and therapy · 2026Review
- Advances in Traditional Chinese Medicine for chronic obstructive pulmonary disease through multi-omics approaches.Frontiers in cell and developmental biology · 2026Review
- The Role of Transforming Growth Factor-β (TGF-β) in Asthma and Chronic Obstructive Pulmonary Disease (COPD).Cells · 2024Review
- A novel Nanocellulose-Gelatin-AS-IV external stent resists EndMT by activating autophagy to prevent restenosis of grafts.Bioactive materials · 2023Article
- Safety and efficacy of Yupingfeng granules in children with recurrent respiratory tract infection: A randomized clinical trial.Pediatric investigation · 2022Article
- Emergence of Ethnomedical COVID-19 Treatment: A Literature Review.Infection and drug resistance · 2021Review
- Mechanism of YuPingFeng in the Treatment of COPD Based on Network Pharmacology.BioMed research international · 2020Article
- Berberine Attenuates Cigarette Smoke Extract-induced Airway Inflammation in Mice: Involvement of TGF-β1/Smads Signaling Pathway.Current medical science · 2019Article
- Curcumin and Curcumol Inhibit NF-Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Okbyungpoongsan (Yupingfeng) for treating allergic rhinitis: A protocol for the systematic review of controlled trials.Medicine · 2018Article
- A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: An example of Yu Ping Feng decoction.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesYu-Ping-Feng-San (YPFS) is a classical traditional Chinese medicine that is widely used for treatment of the diseases in respiratory systems, including chronic obstructive pulmonary disease (COPD) recognized as chronic inflammatory disease. However, the molecular mechanism remains unclear. Here we detected the factors involved in transforming growth factor beta 1 (TGF-β1)/Smad2 signaling pathway and inflammatory cytokines, to clarify whether YPFS could attenuate inflammatory response dependent on TGF-β1/Smad2 signaling in COPD rats or cigarette smoke extract (CSE)-treated human bronchial epithelial (Beas-2B) cells. MATERIALS AND
methodsThe COPD rat model was established by exposure to cigarette smoke and intratracheal instillation of lipopolysaccharide, YPFS was administered to the animals. The efficacy of YPFS was evaluated by comparing the severity of pulmonary pathological damage, pro-inflammation cytokines, collagen related genes and the activation of TGF-β1/Smad2 signaling pathway. Furthermore, CSE-treated cells were employed to confirm whether the effect of YPFS was dependent on the TGF-β1/Smad2 signaling via knockdown Smad2 (Si-RNA), or pretreatment with the inhibitor of TGF-β1.
resultsAdministration of YPFS effectively alleviated injury of lung, suppressed releasing of pro-inflammatory cytokines and collagen deposition in COPD animals (
conclusionYPFS accomplished anti-inflammatory effects mainly by suppressing phosphorylation of Smad2, TGF-β1/Smad2 signaling pathway was required for YPFS-mediated anti-inflammation in COPD rats or CSE-treated Beas-2B cells.
Indexed as
Identifiers
27803787PMC5080430W2526649676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.